Llew Keltner

Llew Keltner, M.D., Ph.D is Chief Executive Officer of EPISTAT, an international healthcare strategy company that he founded in 1972. Dr. Keltner was the Chief Executive Officer of AgonOx, a biotech company developing OX40 agonists for use in cancer therapyfrom 2011 to 2013. He was the President of Novici Biotech, a privately-held gene and protein optimization firm from 2010 to 2011. Dr. Keltner was Chief Executive Officer and President of Light Sciences Oncology, a privately-held biotechnology company developing a late stage, light-activated therapy for certain cancers from 2001 to 2010. From 1997 to 2004, Dr. Keltner was Chief Executive Officer of Metastat, a biotech company focused on cancer metastasis.

Dr. Keltner currently holds positions on the boards of Raptor Pharmaceuticals, (NASDAQ:RPTP), where he served as Chairman from 2013 to 2015, Infostat, BioQ Pharma, Oregon Life Sciences, and Goodwell Technologies. Dr. Keltner is an Associate Professor at Case Western Reserve School of Medicine, and a Guest Lecturer and Director in the Bioethics Program at Columbia University School of Medicine. Dr. Keltner received an M.S. in Epidemiology and Biostatistics, a Ph.D. in Biomedical Informatics and an M.D. from Case Western Reserve University in Cleveland, Ohio.